MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company unlocking the potential of Sonelokimab, the novel investigational Nanobody® for the treatment of inflammation, to revolutionize outcomes for patients.
Sonelokimab (a.k.a. M1095, ALX-0761) unleashes the full power of IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.
Sonelokimab moves the clinical paradigm beyond the traditional antibodies, designed to directly target sites of inflammation and penetrate difficult-to-reach inflamed tissues and joints.
MoonLake builds on a robust clinical data built in recent years by Ablynx, a Sanofi company, and Merck KGaA. MoonLake licensed Sonelokimab from the latter, with full global rights and including a favorable IP position.
The team at MoonLake has a long history and experience with developing immunology assets and growing businesses around new technologies. As a clinical-stage company we are continuously growing and looking for excellent and experienced talent.
The terms Nanobody ® and Nanobodies ® [etc.] are trademarks of Ablynx, a Sanofi company
We value people that are:
We aspire to be positively disruptive in our field, and bold in the way we challenge the norms and each other.
We value people that are:
We value people that are:
Registration as Swiss stock corporation.
Opened Zug office
Series A led by BVF Partners L.P.
Announcement of License Agreement
with Merck KGaA, Darmstadt, Germany
• Global rights
• Royalties in the low teens
• USD 25m upfront + 9.9% ownership
Registration of UK subsidiary
Definitive agreement with Helix Acquisition Corp. to enter into De SPAC business combination and concurrent commitments of leading Biotech investors for a PIPE
Closing of DeSPAC transaction and listing on Nasdaq under ticket MLTX
Achieved positive Phase 2 results in MIRA (HS) trial at week 12
Released full 24-week MIRA (HS) dataset, positioning Nanobody® sonelokimab as a promising treatment for HS
Achieved key Phase 2 results for ARGO (PsA) trial at week 12.
Expanded to the UK with Cambridge office opening
Released full 24-week ARGO (PsA) dataset showing significant improvements with Nanobody® sonelokimab
Launched Phase 3 VELA program for moderate-to-severe HS patients
Initiated Phase 3 IZAR program for active PsA patients
Reached 100 employees, marking significant growth
Initiated three new clinical trials, expanding indication portfolio
Registration as Swiss stock corporation
April 21
May 21
Announcement of License Agreement with Merck KGaA, Darmstadt, Germany
• Global rights
• Royalties in the low teens
• USD 25m upfront + 9.9% ownership
July 21
Oct 21
April 22
Associate Vice-President Legal & Compliance
Chairperson of The Compensation Committee & Chairperson of The Nominating and Corporate Governance Committee
Jorge Santos da Silva, is a co-Founder of MoonLake and has served as the Chief Executive Officer of MoonLake since July 2021, being also a Director of the Board. Prior to MoonLake, he was at McKinsey & Company, Inc. from September 2007 to June 2021, where he was a Senior Partner and led the Pharmaceutical & Medical Products Practice, the Biotech group and the Biosimilars group and advised international biopharmaceutical and biotechnology companies on corporate and business-unit strategy, commercial operating models, R&D, organizational design, M&A and joint ventures. Dr. Santos da Silva was a Postdoctoral Fellow at Cold Spring Harbor Laboratory, NY (USA) and holds a Ph.D. in Neuronal Cell Biology from the University of Turin (Italy) and a MSc in Molecular Biology from the University of Glasgow — Institute of Biological and Life Sciences (United Kingdom) and the European Molecular Biology Laboratory, Heidelberg (Germany). He is also a professor and Board Advisor at the School of Medicine at the Minho University in Portugal.
Dr Andrew J. Phillips is a Director of MoonLake. He is President and Chief Executive Officer of Aleksia Therapeutics and Nexo Therapeutics. He was previously Managing Director at Cormorant Asset Management and also served as Chief Financial Officer of Helix Acquisition Corp. He is a Director at Onkure Therapeutics (Nasdaq: OKUR) and Kestrel Therapeutics. In 2016-2020, he was with C4 Therapeutics, Inc. as Chief Scientific Officer from 2016-2018 and as President and Chief Executive Officer from 2018-2020. In 2014-2016, he served as Senior Director, Center for Development of Therapeutics at the Broad Institute. From 2010 to 2015, Dr. Phillips was a Professor of Chemistry at Yale University, and from 2001 to 2010 he held Professorship positions at the University of Colorado. He holds a B.Sc. in Biochemistry and a Ph.D. in Chemistry from the University of Canterbury in New Zealand.
Dr. Ramnik Xavier, is a Director of MoonLake. Since 2018 at the Broad Institute of MIT and Harvard, he serves as director of the Klarman Cell Observatory. He is also director of the Immunology Program and co-director of the Infectious Disease and Microbiome Program. Since 2013, he is professor of medicine at Harvard Medical School, where he is currently the Kurt J. Isselbacher Professor of Medicine. Since 2018 he is director of the Center for Computational and Integrative Biology and member in the Department of Molecular Biology at Massachusetts General Hospital (MGH). He also served as co-director of the Center for Microbiome Informatics and Therapeutics at MIT since 2014. Dr. Xavier holds an MB ChB (Hons) from the Godfrey Huggins School of Medicine, University of Zimbabwe and a Ph.D. from the University of Groningen.
